InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: north40000 post# 732

Tuesday, 11/15/2016 3:02:52 PM

Tuesday, November 15, 2016 3:02:52 PM

Post# of 2104
well it depends if GILD buys CNAT for instance. With Simtuzumab as monotherapy for Nash LC out of the picture, I think GILD is now pursuing the combination of SIM plus GS-4997 in Advanced Fibrosis, but still in ph2a... so GILD has lost its edge at the moment. Quite frankly , if I was GILD, I would buy CNAT, and become quite possibly a monopolist in the Advance Fibrosis/Cirrhosis segment